Phase 2CompletedAge-related condition
A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause (NIRVANA)
A Randomized, Parallel-group Treatment, Phase 2, Double-blind Pilot Study to Investigate the Efficacy and Safety of Elinzanetant Compared With Placebo for Treatment of Sleep Disturbances Associated With Menopause.
- Sponsor
- Bayer (Industry)
- Enrollment
- 110 enrolled
- Conditions
- Sleep Disturbances Associated With Menopause
- Interventions
- Elinzanetant; Placebo
- Ages
- adults, older adults
- Registry
- NCT06112756, CTIS2023-504955-28-00
Full record on ClinicalTrials.gov
From the registry
Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause. Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop. Sleep disturbances, for example, frequent waking up at night, are a common and bothersome symptom associated with menopause that affects women's quality of life. The study treatment Elinzanetant (also called BAY 3427080) is under development to treat symptoms like hot flashes which are caused by hormonal changes associated with menopause. It may block the activity of a protein that has been found to contribute to sleep disturbances. The main purpose of this study is to learn how does elinzanetant affect sleep disturbances associated with menopause as measured on a sleep test called polysomnography (PSG) as compared with placebo. For this, the researchers will analyze * change in the total number of minutes a participant wakes up at night after going to sleep after 4 weeks of treatment compared to before treatment * change in the total number of minutes a…
Primary outcomes
- Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG)
History
Results first posted
Last registry update
Study completion
Primary completion
Started
Registered
In the news
ConferenceBusiness Wire (opens Business Wire in a new tab)
Bayer presents post hoc sleep analysis of menopause drug elinzanetant’s two pivotal trials
The OASIS-1 and OASIS-2 subanalysis examined PROMIS questionnaire scores in women with moderate-to-severe vasomotor symptoms; Bayer presented the findings at the Menopause Society’s annual meeting.
